I loaded up on shares of drug giant Teva Pharmaceutical (TEVA) over a year ago, and while the share price performance has disappointed, the business results have not. Debt was reduced to plan, headcount has been slashed, plants closed, a reorganization effected, and the drug portfolio thoroughly scrubbed to discontinue unprofitable drugs while emphasizing more profitable ones in which TEVA possesses a cost edge. Two promising patented drugs were launched to rapid sales growth along with a slew of generics. Hundreds more new drugs are in the pipeline with 92 tentatively approved in the US